ANOKION

anokion-logo

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion’s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.

#SimilarOrganizations #People #Financial #Website #More

ANOKION

Social Links:

Industry:
Biotechnology Clinical Trials Therapeutics

Founded:
2010-01-01

Address:
Ecublens, Vaud, Switzerland

Country:
Switzerland

Website Url:
http://www.anokion.com

Total Employee:
11+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
112.61 M USD

Technology used in webpage:
Euro U.S. Server Location Cogent Communications


Similar Organizations

aclaris-therapeutics-logo

Aclaris Therapeutics

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

proteostasis-therapeutics-logo

Proteostasis Therapeutics

Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.


Current Advisors List

jack-nielsen_image

Jack Nielsen Board of Director & Partner @ Anokion
Board_member

tom-woiwode_image

Tom Woiwode Board of Director & Venture Partner @ Anokion
Board_member

florent-gros_image

Florent Gros Board & Managing Director @ Anokion
Board_member

mike-clayman_image

Mike Clayman Chairman Of The Board @ Anokion
Board_member
2018-06-01

harry-welten_image

Harry Welten Board of Director & Chief Financial Officer @ Anokion
Board_member

andré-j-mueller_image

André J. Mueller Board of Director & Chairman @ Anokion
Board_member

patricia-allen_image

Patricia Allen Board Member and Audit Committee Chair @ Anokion
Board_member
2020-09-01

Current Employees Featured

carlo-rizzuto_image

Carlo Rizzuto
Carlo Rizzuto Chief Business Officer @ Anokion
Chief Business Officer
2014-01-01

raj-manchanda_image

Raj Manchanda
Raj Manchanda Chief Development Officer (CDO) @ Anokion
Chief Development Officer (CDO)
2021-01-01

stephan-kontos_image

Stephan Kontos
Stephan Kontos Co-founder & Vice President R&D @ Anokion
Co-founder & Vice President R&D
2015-06-01

melody-swartz_image

Melody Swartz
Melody Swartz Co-Founder @ Anokion
Co-Founder

stephan-kontos_image

Stephan Kontos
Stephan Kontos Chief Scientific Officer @ Anokion
Chief Scientific Officer
2018-03-01

jeffrey-a-hubbell_image

Jeffrey A. Hubbell
Jeffrey A. Hubbell Co-Founder & Chief Scientific Officer @ Anokion
Co-Founder & Chief Scientific Officer
2014-01-01

Founder


jeffrey-a-hubbell_image

Jeffrey A. Hubbell

kristen-m-lorentz_image

Kristen M. Lorentz

melody-swartz_image

Melody Swartz

oscar-buset_image

Oscar Buset

stephan-kontos_image

Stephan Kontos

Acquisitions List

Date Company Article Price
2019-09-11 Kanyos Bio Kanyos Bio acquired by Anokion N/A

Investors List

pfizer-breakthrough-growth-initiative_image

Pfizer Breakthrough Growth Initiative

Pfizer Breakthrough Growth Initiative investment in Venture Round - Anokion

versant-ventures_image

Versant Ventures

Versant Ventures investment in Series B - Anokion

novo-ventures_image

Novo Ventures

Novo Ventures investment in Series B - Anokion

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Series B - Anokion

celgene_image

Celgene

Celgene investment in Series B - Anokion

andr-j-mueller_image

André J. Mueller

André J. Mueller investment in Series A - Anokion

novo-ventures_image

Novo Ventures

Novo Ventures investment in Series A - Anokion

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Series A - Anokion

versant-ventures_image

Versant Ventures

Versant Ventures investment in Series A - Anokion

harry-welten_image

Harry Welten

Harry Welten investment in Series A - Anokion

Official Site Inspections

http://www.anokion.com Semrush global rank: 3.15 M Semrush visits lastest month: 4.77 K

  • Host name: cloudproxy10011.sucuri.net
  • IP address: 192.124.249.11
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Anokion"

Anokion - Crunchbase Company Profile & Funding

Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company’s antigen-specific immune tolerance technology to reduce the …See details»

About Us – Anokion

Toggle navigation. About Us . Overview; Leadership Team; Board of Directors; Science & Platform . What is Immune Tolerance?See details»

Anokion - Funding, Financials, Valuation & Investors - Crunchbase

Sep 11, 2019 Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance. Search Crunchbase. Start Free Trial . ...See details»

Overview - Anokion

Anokion SA (including our wholly-owned subsidiaries Anokion US, Inc. and Kanyos Bio, Inc.) is focused on improving the treatment and outcomes of autoimmune disease. Our proprietary …See details»

Anokion Company Profile 2024: Valuation, Funding & Investors

Anokion General Information Description. Developer of antigen-specific immunotherapy designed to offer services for immune tolerance. The company's immunotherapy focuses on both …See details»

Anokion Company Profile - Office Locations, Competitors ... - Craft

Anokion has 5 employees across 2 locations and $77.61 m in total funding,. See insights on Anokion including office locations, competitors, revenue, financials, executives, subsidiaries …See details»

Anokion - Contacts, Employees, Board Members, Advisors & Alumni

Organization. Anokion . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... About. Anokion has 6 current employee profiles, …See details»

Anokion - Company Profile - Tracxn

Nov 30, 2024 Anokion. has raised a total funding of $112M over 3 rounds. Its first funding round was on May 09, 2014. What are the most recent funding rounds of Anokion? Its latest funding …See details»

Anokion SA - Drug pipelines, Patents, Clinical trials - Synapse

Explore Anokion SA with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 29 news, and 2 literature, Disease Domain:Immune System Diseases, Endocrinology and …See details»

Anokion - Raised $112M Funding from 7 investors - Tracxn

Nov 19, 2024 List of Anokion's institutional investors. Pfizer, located in New York City (United States), made their first investment in Anokion on Oct 18, 2022 in its Series B round.; Celgene, …See details»

Beyond Celiac Drives Recruitment for Promising Anokion Clinical …

Nov 18, 2020 About Anokion Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring …See details»

Leadership Team - Anokion

Nicole Luosey, PMP Senior Vice President, Product and Development OperationsSee details»

Anokion Announces $35 Million Equity Investment from Pfizer

Oct 18, 2022 About Anokion Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune …See details»

Anokion Announces Leadership Team Expansion to Support …

Oct 27, 2022 About Anokion Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune …See details»

Pipeline – Anokion

The company is currently developing KAN-101 for the treatment of celiac disease. KAN-101 is an experimental therapy in early clinical development. Anokion is focused on enrolling and …See details»

Anokion Announces Publication in Science Immunology

Mar 1, 2021 Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal …See details»

Anokion Strengthens its Senior Leadership with Promotions and …

Sep 7, 2023 Cambridge, Mass. and Lausanne, Switzerland, September 7, 2023 – Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring …See details»

Anokion Announces Progress Across Pipeline of Novel …

Jan 6, 2022 Anokion SA is a clinical-stage Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring …See details»

Anokion Announces Publication in Science Immunology

Mar 1, 2021 Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the …See details»

linkstock.net © 2022. All rights reserved